Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

7/29/2022 Import of Veterinary Drugs and Feed Supplements to Russia (June and Q1–Q2 2022)

In January–June 2022, Russia imported 18.5 billion rubles’ worth of veterinary drugs (customs clearance and VAT included), down 5% from the same period in 2021. The import of feed supplements was 21.9 billion rubles, up 4.1% from January–June 2021. In physical terms, the growth rates were negative for both groups: –1.3% for veterinary drugs, with 15.7 million packages imported, and –15.5% for feed supplements, with 68,000 tons imported.

7/28/2022 Pharmaceutical Drug Production in Russia (June and Q1–Q2 2022)

In January–June 2022, Russia manufactured 366 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 28.4% from January–June 2021. In physical terms, the production volume was 2.14 billion packages, up 5.9% from the same period in 2021. If calculated in minimum dosage units (MDU), Russia produced 40.5 billion MDUs, up 3.3% from January–June 2021.

7/27/2022 API Import to Russia (June and Q1–Q2 2022)

In January–June 2022, Russia imported 106.4 billion rubles’ worth of APIs (customs clearance and VAT included), up 3.7% from January–June 2021, a five-year low. In physical terms, the growth rate was 21%, a twelve-year high, with around 10,000 tons imported, a six-month high.

7/26/2022 Study by RNC Pharma and Medvestnik: 78% of Russian Doctors Expect Salaries to Drop after New Covid Payments Are Introduced, Young Physicians at Risk

Only 1.1% expect a salary raise after the changes to payments to healthcare workers dealing with COVID-19 patients are introduced, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. At the same times, about 2.2% of the physicians believe that their salaries might decrease only a little, by no more than 10%. Another 2.9% expect neither an increase nor decrease, saying that “everything will remain more or less the same.”

7/25/2022 Pharmaceutical Drug Import to Russia (June and Q1–Q2 2022)

In Q1–Q2 2022, Russia imported 397.8 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 8.7% from Q1–Q2 2021. As for bulk drugs, the import volume was 94.4 million rubles, up as much as 32.6% from Q1–Q2 2021. In physical terms, however, the growth rates were negative for both groups: –9.4% for ready-made drugs, with 803 million packages imported, and –32.7% for bulk drugs, with 731.4 million MDUs (minimum dosage units) imported.

All news [331]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.